title: Current challenges and novel treatment strategies in double hit lymphomas.
abstract: High-grade B-cell lymphomas with recurrent chromosomal break points have been termed 'double hit lymphoma' (DHL). The most commonly seen DHL is diffuse large B-cell lymphoma (DLBCL) with t(14;18) and t(8;14) or t(8;22) resulting in overexpression of BCL2 and MYC, respectively. The increased proliferation due to MYC overexpression, without the ability for an apoptotic brake as a result of BCL2 overexpression, results in 'the perfect storm of oncogenesis'. Thus this disease presents a number of diagnostic and therapeutic challenges for the hematologist. The first and foremost challenge is to recognize the DHL. As different morphological entities can be affected it is incumbent on pathologists and clinicians to maintain a high index of suspicion especially in disease that appears unusually aggressive or refractory to therapy. Diagnosis by fluorescence in situ hybridization (FISH) is a sensitive and specific method for detection of the disease but is time-consuming and expensive. While detection by immunohistochemistry (IHC) is sensitive and correlates with survival, standardized methods for this are not widely agreed upon. The second and equally important challenge in DHL is optimizing clinical outcome in a group of patients for whom the prognosis is widely regarded as poor. While improvements have been achieved by dose escalating standard chemotherapeutic regimens, many patients continue to do badly. Furthermore as a disease of aging many patients are unsuitable for dose-intensive chemotherapy regimens. There are now multiple novel targeted agents in various stages of clinical development that offer hope for better outcomes without undue toxicity. Among the most exciting of these developments include specific inhibitors of both BCL2 and MYC.
authors.affiliation: The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade Parkville, Victoria 3052, Australia.
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Anderson
authors.affiliation: Department of Pathology, Royal Melbourne Hospital, Parkville, Australia.
authors.forename: Alpha
authors.initials: A
authors.lastname: Tsui
authors.affiliation: Victorian Cancer Cytogenetics Service, St Vincent's Hospital, Fitzroy, Australia.
authors.forename: Meaghan
authors.initials: M
authors.lastname: Wall
authors.affiliation: Departments of Medical Biology and Medicine, Faculty of Medicine, University of Melbourne, Parkville, Australia.
authors.forename: David C S
authors.initials: DC
authors.lastname: Huang
authors.affiliation: Department of Clinical Hematology and Bone Marrow Transplant, Royal Melbourne Hospital, Parkville, Australia.
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Roberts
keywords: BCL-2; MYC; diffuse large B-cell lymphoma; double hit lymphoma
references.citation: Exp Hematol. 2011 Aug;39(8):817-28.e1
references.pmid: 21640157
references.citation: Cell. 2011 Sep 16;146(6):904-17
references.pmid: 21889194
references.citation: Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix
references.pmid: 18954744
references.citation: Cancer Cell. 2008 Dec 9;14(6):447-57
references.pmid: 19061836
references.citation: Blood. 2004 Aug 1;104(3):634-41
references.pmid: 15016643
references.citation: J Clin Oncol. 2013 Aug 10;31(23):2912-9
references.pmid: 23835718
references.citation: J Clin Oncol. 2010 Jul 10;28(20):3360-5
references.pmid: 20498406
references.citation: N Engl J Med. 2002 Jan 24;346(4):235-42
references.pmid: 11807147
references.citation: J Clin Oncol. 2012 Oct 1;30(28):3439-43
references.pmid: 22949152
references.citation: Nature. 2005 Jun 2;435(7042):677-81
references.pmid: 15902208
references.citation: Blood. 2013 Dec 12;122(25):4129-39
references.pmid: 24055823
references.citation: J Clin Oncol. 2014 Jan 1;32(1):44-50
references.pmid: 24043741
references.citation: Cancer Genet Cytogenet. 2001 Apr 1;126(1):45-51
references.pmid: 11343778
references.citation: PLoS One. 2012;7(4):e33813
references.pmid: 22511926
references.citation: J Clin Oncol. 2007 Mar 1;25(7):805-12
references.pmid: 17327602
references.citation: Eur J Haematol. 2012 Jul;89(1):63-71
references.pmid: 22510149
references.citation: J Clin Oncol. 2005 Aug 1;23(22):5027-33
references.pmid: 15955905
references.citation: Nat Med. 2013 Feb;19(2):202-8
references.pmid: 23291630
references.citation: Blood. 2010 Sep 2;116(9):1498-505
references.pmid: 20519624
references.citation: Nature. 1992 Oct 8;359(6395):554-6
references.pmid: 1406976
references.citation: Br J Haematol. 2015 Mar;168(6):784-95
references.pmid: 25529575
references.citation: Eur J Haematol. 2014 Jan;92(1):42-8
references.pmid: 24118498
references.citation: Blood. 2009 Oct 22;114(17):3533-7
references.pmid: 19704118
references.citation: Blood. 2013 Mar 21;121(12):2253-63
references.pmid: 23335369
references.citation: Lancet Oncol. 2010 Dec;11(12):1149-59
references.pmid: 21094089
references.citation: Am J Pathol. 1990 Aug;137(2):225-32
references.pmid: 2201196
references.citation: Haematologica. 2013 Oct;98(10):1554-62
references.pmid: 23716551
references.citation: J Clin Oncol. 2012 Oct 1;30(28):3460-7
references.pmid: 22665537
references.citation: Blood. 2003 Jun 1;101(11):4279-84
references.pmid: 12576316
references.citation: Blood. 2010 Sep 23;116(12):2040-5
references.pmid: 20548096
references.citation: Genes Chromosomes Cancer. 1999 Jun;25(2):123-33
references.pmid: 10337996
references.citation: Blood. 2014 Oct 9;124(15):2354-61
references.pmid: 25161267
references.citation: Mod Pathol. 2012 Jan;25(1):145-56
references.pmid: 22002575
references.citation: J Clin Oncol. 2008 Jun 1;26(16):2717-24
references.pmid: 18378569
references.citation: Cancer Res. 2008 May 1;68(9):3421-8
references.pmid: 18451170
references.citation: Br J Haematol. 2014 Sep;166(6):891-901
references.pmid: 24943107
references.citation: Blood. 2005 Oct 15;106(8):2912-9
references.pmid: 15994282
references.citation: Genes Chromosomes Cancer. 1990 Jul;2(2):147-58
references.pmid: 2278969
references.citation: Blood Cells Mol Dis. 2010 Dec 15;45(4):317-23
references.pmid: 20817505
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17961-6
references.pmid: 19004807
references.citation: J Clin Oncol. 2015 Feb 20;33(6):540-9
references.pmid: 25154820
references.citation: Cancer. 2012 Mar 15;118(6):1566-73
references.pmid: 21882178
references.citation: Blood. 2007 Jul 1;110(1):54-8
references.pmid: 17387223
references.citation: Blood. 2011 Feb 24;117(8):2319-31
references.pmid: 21119107
references.citation: J Clin Oncol. 2010 Sep 20;28(27):4184-90
references.pmid: 20660832
references.citation: Nature. 2010 Dec 23;468(7327):1067-73
references.pmid: 20871596
references.citation: Blood. 2009 Sep 10;114(11):2273-9
references.pmid: 19597184
references.citation: Lancet Oncol. 2006 May;7(5):379-91
references.pmid: 16648042
references.citation: Blood. 2011 Jan 13;117(2):591-4
references.pmid: 20959606
references.citation: Leukemia. 2009 Feb;23(2):225-34
references.pmid: 18923440
references.citation: Blood Cells Mol Dis. 2001 Jan-Feb;27(1):206-16
references.pmid: 11358381
references.citation: Blood. 2013 Mar 21;121(12):2285-8
references.pmid: 23341542
references.citation: Br J Haematol. 2012 Jan;156(2):234-44
references.pmid: 22098541
references.citation: Nat Med. 2004 Feb;10(2):145-7
references.pmid: 14745444
references.citation: N Engl J Med. 2014 Mar 13;370(11):997-1007
references.pmid: 24450857
references.citation: Cell. 2007 Mar 23;128(6):1173-86
references.pmid: 17382885
references.citation: Cell Death Differ. 2007 May;14(5):943-51
references.pmid: 17205078
references.citation: Haematologica. 2007 Oct;92(10):1335-42
references.pmid: 18024371
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Leukemia. 2009 Apr;23(4):777-83
references.pmid: 19151788
references.citation: Blood. 2002 Jun 15;99(12):4265-75
references.pmid: 12036852
references.citation: Am J Surg Pathol. 2012 Apr;36(4):612-9
references.pmid: 22314191
references.citation: J Clin Oncol. 2012 Feb 10;30(5):488-96
references.pmid: 22184378
references.citation: J Clin Oncol. 2012 Oct 1;30(28):3452-9
references.pmid: 22851565
references.citation: Leuk Lymphoma. 2015 Jul;56(7):1928-9
references.pmid: 25407655
references.citation: Am J Surg Pathol. 2010 Mar;34(3):327-40
references.pmid: 20118770
references.citation: Clin Cancer Res. 2003 Jun;9(6):2133-9
references.pmid: 12796378
references.citation: Clin Cancer Res. 2014 Jan 1;20(1):213-20
references.pmid: 24132920
references.citation: Blood. 2012 Aug 9;120(6):1210-7
references.pmid: 22734071
references.citation: J Clin Oncol. 2010 Apr 20;28(12):2085-93
references.pmid: 20308665
references.citation: Blood. 2012 May 17;119(20):4619-24
references.pmid: 22408263
references.citation: Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3879-84
references.pmid: 22343534
references.citation: Br J Haematol. 2014 Aug;166(3):369-74
references.pmid: 24761809
references.citation: Semin Hematol. 2014 Jul;51(3):219-27
references.pmid: 25048785
references.citation: Leuk Lymphoma. 2015 Jul;56(7):2146-52
references.pmid: 25373508
references.citation: Ann Oncol. 2011 Jul;22(7):1622-1627
references.pmid: 21228334
references.citation: Leukemia. 2008 Dec;22(12):2226-9
references.pmid: 18754028